secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zai Lab Ltd (ZLAB)
CIK:        0001704292
Form:       8-K
Filed at:   2022-01-06T23:59:59+00:00
Accession:  0001193125-22-003149
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zai Lab's NDA for margetuximab accepted by China NMPA for HER2+ breast cancer
-----------------------------------------------------------------------------

- NMPA accepted NDA for margetuximab, a HER2-targeted monoclonal antibody, for metastatic HER2+ breast cancer with 2+ prior anti-HER2 therapies.
- Margetuximab is the only HER2-targeted agent to show PFS improvement vs trastuzumab in head-to-head Phase 3 SOPHIA trial.
- NDA acceptance marks Zai Lab's sixth NDA acceptance by NMPA and expands women's oncology franchise.
- Bridging study in Chinese patients met primary endpoint of PFS by BICR; safety consistent with SOPHIA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704292/000119312522003149/0001193125-22-003149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704292/000119312522003149/d274826d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-003149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer